A groundbreaking study has revealed that millions of individuals diagnosed with breast cancer may be able to avoid the often debilitating effects of chemotherapy, thanks to a pioneering DNA test. Conducted by researchers at University College London (UCL), this international trial suggests that over two-thirds of participants could receive hormone therapy alone, significantly reducing their exposure to the harsh side effects associated with traditional chemotherapy.
A Game-Changing Discovery
The research, which included more than 4,000 newly diagnosed patients aged 40 and older from the UK, Norway, Sweden, Australia, New Zealand, and Thailand, employed a genetic test known as Prosigna. This test analyses the activity of 50 genes that play a crucial role in breast cancer proliferation, allowing clinicians to assess a patient’s risk of recurrence. Those who received a low-risk score—comprising approximately two-thirds of the participants—were advised against chemotherapy. Remarkably, the five-year survival rate for these patients stood at 93.7%, closely mirroring the 94.9% survival rate of those who did undergo chemotherapy.
Historically, chemotherapy has been a standard follow-up treatment after surgical intervention to remove tumours, especially for patients whose early-stage cancer has spread to nearby lymph nodes. However, there has been growing concern among medical professionals regarding the limited benefits this treatment offers to patients with the most prevalent forms of breast cancer.
Implications for Patient Care
The UCL study indicates that around 5,000 patients within the NHS could potentially avoid chemotherapy each year as a direct result of these findings. Karen Bonham, a 64-year-old participant from Cardiff, expressed her relief, stating that the results felt like “Christmas” to her. Bonham, who benefited from the Prosigna test, has opted for radiotherapy and hormone therapy over the past eight years instead of enduring chemotherapy. Her experience underscores the emotional turmoil that often accompanies a cancer diagnosis. “It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive,” she reflected.
Professor David Miles, a prominent figure in cancer research, described the study’s findings as “practice-changing.” He asserted that the ability to identify patients who would derive no benefit from chemotherapy represents a significant advancement in personalised medicine. “We can now confidently predict many patients will get no benefit at all, and therefore there’s no need for them to have the chemotherapy,” he noted in an interview. Historically, the approach involved administering chemotherapy to a large cohort of women, with only a small fraction reaping its benefits.
A Positive Response from Patients
The findings have sparked enthusiasm among those affected by breast cancer. Tanya Hutson, who underwent chemotherapy after her diagnosis in 2022, hailed the new DNA test as “absolutely amazing.” She expressed her hope that the research would change the treatment landscape for many, stating, “For all these people out there who don’t need it but are still getting it—it’s an absolute game changer.” Her experience with chemotherapy, which she described as “brutal,” highlights the necessity for advancements in treatment protocols that prioritise patient wellbeing.
While the results of the study are promising, researchers caution that it remains to be seen whether these findings will extend to patients under the age of 40. The development of a tailored treatment approach could represent a paradigm shift in managing breast cancer, but further research is necessary to validate these new protocols across all age groups.
Why it Matters
The introduction of a DNA test that can accurately identify patients who can forgo chemotherapy not only promises to alleviate the physical and emotional burdens associated with cancer treatment but also represents a significant leap forward in the field of personalised medicine. By tailoring treatment plans based on genetic information, healthcare providers can enhance patient outcomes while simultaneously reducing unnecessary interventions. This study could redefine the standard of care for breast cancer, underscoring the importance of continued investment in medical research and the quest for more effective, less invasive treatment options. As we navigate an era of precision medicine, the potential to improve the lives of millions is not just a possibility; it is becoming a reality.
